Physician profile
Michael A Schechter
NPI 1801231311
$11,903.78
in general payments reported to CMS, 2019-2025
40 companies · $3,001 in 2025
The $3,001 reported for 2025 was more than what 75% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $903 · 2021: $1,161 · 2022: $1,627 · 2023: $2,216 · 2024: $2,996 · 2025: $3,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,127 · Travel and Lodging: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,127.20 |
| Travel and Lodging | $1,084.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,910.98 | 2020-2025 | Triclip, Jot Dx, Aveir |
| Medtronic, INC. | $1,962.85 | 2021-2025 | Corevalve Evolut R, Micra, Linq II |
| Boston Scientific Corporation | $942.87 | 2020-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Bodyguardian |
| Edwards Lifesciences Corporation | $855.52 | 2020-2024 | Carpentier-Edwards Physio II Annuloplasty Ring, Mitris Resilia Mitral Valve, Pascal |
| Abiomed | $846.31 | 2021-2024 | Impella |
| Atricure, INC. | $410.35 | 2022-2025 | Synergy Ablation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $382.07 | 2020-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $284.23 | 2020-2023 | Wainua, Farxiga |
| Pfizer INC. | $200.48 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $176.26 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.67 | 2023-2025 | Jardiance |
| Penumbra, INC. | $145.32 | 2021-2024 | Penumbra System, Smart Coil, Indigo System |
| Amarin Pharma, INC. | $130.58 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $129.65 | 2024 | Gore Cardioform Septal Occluder |
| Cardiva Medical, INC. | $124.64 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $111.40 | 2020 | |
| Cardiovascular Systems INC. | $100.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $98.49 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $96.87 | 2024-2025 | Eliquis, Camzyos |
| Heartflow, INC. | $88.28 | 2022 | |
| Agepha Pharma Fz LLC | $83.80 | 2024-2025 | Lodoco |
| Cvrx, INC. | $82.46 | 2023-2025 | Barostim Neo System |
| Teleflex LLC | $63.94 | 2020-2022 | |
| Amgen INC. | $63.76 | 2020-2022 | |
| Kestra Medical Technology Services, INC. | $53.07 | 2023-2024 | Assure Wcd |
| Shockwave Medical, INC | $51.17 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cleerly, INC. | $46.23 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Biotronik INC. | $43.16 | 2023 | Biomonitor |
| Lexicon Pharmaceuticals, INC. | $37.36 | 2023 | Inpefa |
| Philips North America LLC | $36.30 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Acutus Medical, INC. | $32.30 | 2021-2022 | |
| Becton, Dickinson and Company | $23.06 | 2024 | Venclose Maven Catheter |
| Glaxosmithkline, LLC. | $19.54 | 2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $17.96 | 2024 | Ozempic |
| Vital Connect, INC | $16.75 | 2025 | Vitalpatch Rtm |
| Arbor Pharmaceuticals, INC. | $16.45 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.44 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $16.44 | 2024 | Arcalyst |
| Chiesi USA, INC. | $15.21 | 2021 | |
| Merck Sharp & Dohme LLC | $14.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.